SaxoCell Conference 2026

SaxoCell Conference 2026
Go back

SaxoCell Conference 2026

From Lab to Life: Advancing Cell and Gene Therapies Together

Join us at the SaxoCell Conference 2026 in Dresden, where leading minds from science,industry, and politics come together to shape the future of safe and accessible cell and genetherapies — bridging innovation and implementation.

The SaxoCell Conference 2026 is your opportunity to engage with experts, innovators, and decision makers in the field of cell and gene therapies. As part of the BMBF Clusters4Future initiative, SaxoCell is one of Germany’s leading centres dedicated to researching new applications and production methods for personalised therapies and ‘living drugs’.

What to Expect:

  • Insights into the latest scientific advancements in cell and gene therapies.
  • Opportunities to network with professionals from academia, industry, and policy.
  • Discussions on how Germany is contributing to the future of Cell and Gene Therapy.

Date: 02 – 03 June 2026
Location: Penck Hotel, Dresden

Whether you’re a scientist, industry leader, or policymaker, the SaxoCell Conference offers a platform to
exchange ideas and collaborate on shaping the future of healthcare.

You can find more information about SaxoCell at www.saxocell.de

Register now to be part of this important event!

https://eveeno.com/saxocell_conference_2026

BioRN members receive a 20 % discount.

Please contact Nicole Hecht (nh(at)biorn.org) for the Discount Code and more Information.

register now

Our latest News

discover more
Member2Member: Where expertise meets the community

Member2Member: Where expertise meets the community

Every company in the bioRN network has a story to tell. More importantly, every company has knowledge that can help others move faster, avoid mistakes and spark new collaborations. That is the idea behind bioRN’s Member2Member series. Instead of traditional company presentations, Member2Member opens the doors to our member organisations and puts their expertise centre […]

read more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

read more
Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

read more

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp